{
    "clinical_study": {
        "@rank": "68984", 
        "arm_group": [
            {
                "arm_group_label": "Icotinib", 
                "arm_group_type": "Experimental", 
                "description": "125 mg three times daily (375 mg per day) by mouth"
            }, 
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Active Comparator", 
                "description": "1 tablet three times daily by mouth"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to compare 2 years of disease-free survival (DFS) of Icotinib\n      and placebo in the treatment of patients who EGFR mutation-positive II-IIIA lung\n      adenocarcinoma."
        }, 
        "brief_title": "Icotinib Versus Placebo as Adjuvant Therapy in EGFR-mutant Lung Adenocarcinoma", 
        "completion_date": {
            "#text": "December 2020", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "EGFR Positive Non-small Cell Lung Cancer", 
            "Adenocarcinoma"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Adenocarcinoma", 
                "Carcinoma, Non-Small-Cell Lung", 
                "Lung Neoplasms"
            ]
        }, 
        "detailed_description": {
            "textblock": "This study is designed to compare 2 years of disease-free survival (DFS) of Icotinib and\n      placebo in the treatment of patients who EGFR mutation-positive II-IIIA lung adenocarcinoma.\n\n      Primary Outcome Measure:\n\n      Disease-free survival between Icotinib group and placebo group.\n\n      Secondary Outcome Measures:\n\n      Overall survival between Icotinib group and placebo group. Lung cancer symptoms and\n      health-related quality of life (HRQoL) . Number of participants with adverse events."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Pathologically confirmed lung adenocarcinoma after surgical resection\n\n          -  Stage II-IIIA disease according to 7th edition of TNM staging\n\n          -  Patients must harbor sensitive EGFR gene mutation (19/21)\n\n        Exclusion Criteria:\n\n          -  Previous systemic anti-tumor therapy, including chemotherapy or targeted\n             therapy(Including but not limited to monoclonal antibodies, small molecule tyrosine\n             kinase inhibitor, etc\n\n          -  Presence of metastatic disease\n\n          -  Other co-existing malignancies or malignancies diagnosed within the last 5 years with\n             the exception of basal cell carcinoma or cervical cancer in situ\n\n          -  Any unresolved chronic toxicity from previous anticancer therapy"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "75 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "300", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "April 24, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02125240", 
            "org_study_id": "BD-IC-IV-59"
        }, 
        "intervention": [
            {
                "arm_group_label": "Icotinib", 
                "description": "125 mg three times daily (375 mg per day) by mouth", 
                "intervention_name": "Icotinib", 
                "intervention_type": "Drug", 
                "other_name": [
                    "BPI-2009", 
                    "Conmana"
                ]
            }, 
            {
                "arm_group_label": "Placebo", 
                "description": "1 tablet three times daily by mouth", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug", 
                "other_name": "Placebo"
            }
        ], 
        "is_fda_regulated": "No", 
        "lastchanged_date": "April 24, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Beijing", 
                        "country": "China", 
                        "state": "Beijing", 
                        "zip": "100021"
                    }, 
                    "name": "Cancer Hospital, Chinese Academy of Medical Science"
                }, 
                "investigator": {
                    "last_name": "Yuan-Kai Shi, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Beijing", 
                        "country": "China", 
                        "state": "Beijing", 
                        "zip": "100044"
                    }, 
                    "name": "Peking University People's Hospital"
                }, 
                "investigator": {
                    "last_name": "Jun Wang, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Beijing", 
                        "country": "China", 
                        "state": "Beijing", 
                        "zip": "100048"
                    }, 
                    "name": "304 Hospital of PLA"
                }, 
                "investigator": {
                    "last_name": "Wen-Hua Xiao, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Beijing", 
                        "country": "China", 
                        "state": "Beijing", 
                        "zip": "100853"
                    }, 
                    "name": "People's Liberation Army General Hospital (301 Hospital)"
                }, 
                "investigator": {
                    "last_name": "Yi Hu, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Beijing", 
                        "country": "China", 
                        "state": "Beijing", 
                        "zip": "100053"
                    }, 
                    "name": "Xuanwu Hospital, Capital Medical University"
                }, 
                "investigator": {
                    "last_name": "Xiu-Yi Zhi, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Beijing", 
                        "country": "China", 
                        "state": "Beijing", 
                        "zip": "100005"
                    }, 
                    "name": "Beijing Hospital"
                }, 
                "investigator": {
                    "last_name": "Gang Cheng, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Beijing", 
                        "country": "China", 
                        "state": "Beijing", 
                        "zip": "100000"
                    }, 
                    "name": "Beijing Chaoyang Hospital"
                }, 
                "investigator": {
                    "last_name": "Hui Li, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Beijing", 
                        "country": "China", 
                        "state": "Beijing", 
                        "zip": "100029"
                    }, 
                    "name": "China-japan friendship hospital in Beijing"
                }, 
                "investigator": {
                    "last_name": "De-Ruo Liu, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Beijing", 
                        "country": "China", 
                        "state": "Beijing", 
                        "zip": "100034"
                    }, 
                    "name": "Peking University First Hospital"
                }, 
                "investigator": {
                    "last_name": "Jian Li, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Beijing", 
                        "country": "China", 
                        "state": "Beijing", 
                        "zip": "101149"
                    }, 
                    "name": "Capital Medical University, Beijing Chest Hospital"
                }, 
                "investigator": {
                    "last_name": "Shu-Cai Zhang, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Beijing", 
                        "country": "China", 
                        "state": "Beijing", 
                        "zip": "100005"
                    }, 
                    "name": "Beijing Union Medical College Hospital"
                }, 
                "investigator": {
                    "last_name": "Shan-Qing Li, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }
        ], 
        "location_countries": {
            "country": "China"
        }, 
        "number_of_arms": "2", 
        "official_title": "Icotinib as an Adjuvant Therapy for Stage II-IIIA Adenocarcinoma With EGFR Mutation: A Placebo-controlled, Randomized, Double-blind, Phase III Study", 
        "overall_contact": {
            "last_name": "Yuan-Kai Shi, MD", 
            "phone": "010-87788293"
        }, 
        "overall_official": {
            "affiliation": "Cancer Hospital, Chinese Academy of Medical Science", 
            "last_name": "Yuan-Kai Shi, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "China: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "December 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "DFS was defined as the time from the date of first dose of study medication to the date of  death due to  disease recurrence or disease progression.", 
            "measure": "Disease-free  survival", 
            "safety_issue": "No", 
            "time_frame": "24  months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02125240"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "OS was assessed via calculation of the time to death due to any cause from the date of randomization. A patient was censored at the last date they were known to be alive.", 
                "measure": "Overall survival", 
                "safety_issue": "No", 
                "time_frame": "60 months"
            }, 
            {
                "measure": "Lung cancer symptoms and health-related quality of life (HRQoL) differences", 
                "safety_issue": "No", 
                "time_frame": "60 months"
            }, 
            {
                "measure": "Number of participants with adverse events", 
                "safety_issue": "No", 
                "time_frame": "24 months"
            }
        ], 
        "source": "Betta Pharmaceuticals Co.,Ltd.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Betta Pharmaceuticals Co.,Ltd.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "May 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 2014"
    }
}